CA125 in ovarian cancer
نویسندگان
چکیده
منابع مشابه
CA125 in ovarian cancer.
A quarter of a century since its discovery, circulating CA125 antigen is recommended for clinical use in the USA for ovarian cancer screening of high-risk women with ovaries, despite its limited sensitivity and specificity. Recent findings suggest that CA125 might also serve as a predictive marker for pre-invasive ovarian carcinoma. Methods to quantify circulating CA125 evolved toward sensitive...
متن کاملPersonalizing CA125 levels for ovarian cancer screening.
Screening trials for the early detection of ovarian cancer in the general population and in patients at a high risk for this disease have so far failed to show a reduction of ovarian cancer-specific mortality. Current screening modalities include pelvic examinations, transvaginal ultrasounds, and cancer antigen 125 (CA125) serum marker levels, which are associated with a high false-positive rat...
متن کاملMonitoring ovarian cancer: CA125 trial stirs controversy.
M onitoring ovarian cancer with regular blood tests for the CA125 biomarker is a firmly embedded practice in oncology, the theory being that rising CA125 levels may indicate a recurrence, which can be treated effectively upon early detection. But results from a new randomized, controlled trial presented at the annual meeting of the American Association of Clinical Oncology (ASCO) earlier this y...
متن کاملCorrelation of Preoperative HE-4 and CA125 with Ovarian Cancer Staging in Ahvaz Imam Khomeni Hospital
Background: Given that ovarian cancer symptoms are nonspecific and that appropriate surgical staging and pathological grading are important for the best treatment and prognosis of patients, this study aimed to determine the correlation of preoperative serum levels of CA125 and He4 with staging and grading. Materials and Methods: This cross-sectional study recruited 29 patients with epithelial...
متن کاملCA125 immune complexes in ovarian cancer patients with low CA125 concentrations.
BACKGROUND About 20% of women with ovarian cancer have low concentrations of serum cancer antigen 125 (CA125), and this important tumor marker cannot be used to monitor their disease. The measured concentration for mucin 1 (MUC1), or CA15-3, another tumor marker, can be lowered in breast and ovarian cancer patients when circulating immune complexes (CICs) containing antibodies bound to the free...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomarkers in Medicine
سال: 2007
ISSN: 1752-0363,1752-0371
DOI: 10.2217/17520363.1.4.513